慢性淋巴细胞白血病 中国就医指南

Chronic Lymphocytic Leukemia (CLL) is a slow-progressing hematologic malignancy characterized by the clonal expansion of mature-appearing but immunologically dysfunctional B lymphocytes in the bone marrow, peripheral blood, and lymphoid tissues. It is the most common adult leukemia in Western countries and increasingly recognized in Asia, including China. Pathogenically, CLL arises from genetic alterations—including deletions in chromosome 13q, 11q, or 17p; mutations in TP53, NOTCH1, SF3B1, and ATM; and aberrant B-cell receptor signaling—that disrupt apoptosis, cell cycle regulation, and DNA repair. These abnormalities confer survival advantages to malignant B cells, enabling their accumulation over years without immediate symptoms. Epidemiologically, CLL predominantly affects older adults, with median age at diagnosis around 70 years; incidence rises sharply after age 60. In China, age-standardized incidence is lower than in North America or Europe (approximately 0.5–1.2 per 100,000 vs. 4–5 per 100,000), but prevalence is increasing due to aging populations and improved diagnostics. Risk factors include advanced age, male sex (male-to-female ratio ~1.5–2:1), family history of CLL or other lymphoproliferative disorders, and certain germline polymorphisms (e.g., in the DLEU2 or IRF8 loci). Occupational exposures (e.g., herbicides, solvents) remain inconclusive in Asian cohorts. Unlike aggressive leukemias, CLL often follows an indolent course: up to 30–40% of patients never require treatment and are managed with active surveillance. However, symptomatic disease—marked by fatigue, recurrent infections, unexplained weight loss, night sweats, lymphadenopathy, splenomegaly, or cytopenias due to bone marrow infiltration—significantly impairs quality of life. Patients report diminished physical functioning, anxiety about disease progression, treatment-related toxicities (e.g., immune suppression, infusion reactions), and psychosocial burden from long-term monitoring. With modern targeted therapies (e.g., BTK inhibitors like ibrutinib and acalabrutinib, BCL-2 inhibitors like venetoclax), overall survival has markedly improved—median OS now exceeds 10–15 years for many newly diagnosed patients—but lifelong management, financial strain, and cumulative toxicity remain challenges. Early detection via routine blood tests (elevated absolute lymphocyte count >5×10⁹/L sustained >3 months) and flow cytometry confirmation (CD5+, CD19+, CD20dim, CD23+, sIgdim) enables timely risk stratification using tools like the CLL-IPI (International Prognostic Index). Comprehensive care requires multidisciplinary input from hematologists, oncologists, supportive care specialists, and patient navigators to optimize clinical outcomes and preserve functional well-being.

# 慢性淋巴细胞白血病（CLL）治疗方案与费用明细（血液科）

一、非手术/药物治疗方案

适用人群：初治无症状（Binet A期）、有症状但无高危突变（如未累及TP53/17p缺失）、老年或合并症多者。

• •一线方案（BTK抑制剂）：奥布替尼（国产）60–80万元/年；伊布替尼（原研）96–120万元/年
• •免疫化疗方案：FCR（氟达拉滨+环磷酰胺+利妥昔单抗）：单疗程4.2–6.5万元（含药费+输注+监测）
• •检查费：流式细胞术（CD5/CD19/CD23）1,200元；FISH检测（17p/11q/13q）2,800元；IGHV突变分析3,500元

二、核心介入/靶向强化方案

适用人群：TP53缺失/突变、复发难治、进展迅速者。

• •BCL-2抑制剂联合方案（维奈托克+利妥昔单抗）：12周期总费用约32–45万元（含维奈托克梯度给药期监护）
• •CAR-T治疗（临床试验外获批适应症）：仅限二线后复发患者，单次治疗费用85–110万元（含淋巴细胞采集、制备、回输及ICU级支持）
• •术前/基线检查费：骨髓穿刺+活检3,600元；PET-CT 7,200元；MRD（二代测序）4,500元

三、特殊复杂情况处理

• •Richter转化：需按弥漫大B细胞淋巴瘤方案治疗（R-CHOP），单周期1.8–2.6万元，共6周期；若伴中枢浸润，鞘内注射+全脑放疗另增3.2–4.8万元
• •严重免疫缺陷相关感染：IVIG替代+抗真菌/抗病毒长程治疗，月均费用1.5–3.0万元

方案快速选择指南

✅ 预算有限/老年患者：优选奥布替尼单药（年费≤80万）+定期MRD监测 ✅ 年轻高危初治患者：首选维奈托克+利妥昔单抗（12周期总控费≤45万） ✅ TP53异常复发者：评估CAR-T可及性（优先入组医保谈判通道医院） ✅ 经济困难患者：申请国家医保谈判药品（伊布替尼、维奈托克已纳入，年自付约2–5万元）